Previous 10 | Next 10 |
The news is a bit stale, but G1 Therapeutics (NASDAQ: GTHX ) has agreed to co-promote trilaciclib in the U.S. and Puerto Rico with privately held Boehringer Ingelheim (BI) for small cell lung cancer. More news on: G1 Therapeutics, Inc., Healthcare stocks news, Read more ...
- Partnership leverages Boehringer Ingelheim’s oncology expertise to lead trilaciclib SCLC launch sales engagements - G1 to retain full development and commercialization rights and book revenue for trilaciclib -New Drug Application (NDA) for trilaciclib submitted in June 2020 ...
Deals and Financings VistaGen (VTGN) of South San Francisco out-licensed China/Southeast Asia rights for a novel anxiety treatment to EverInsight Therapeutics, a China in-licensing company, in a $177 million agreement. VistaGen's PH94B is a rapid-onset neurosteroid drug candidate for mul...
NOTE: MM = millions Our analysis concludes G1 Therapeutics (GTHX) is materially undervalued because it trades for less than 1 times estimated peak annual revenues of its primary therapy in development, should it be approved by the FDA by 12/31/2020, and only a small fraction of estimated pea...
G1 Therapeutics (NASDAQ: GTHX ) and Genor Biopharma Co. announce an exclusive license agreement for the development and commercialization of G1's lerociclib in the Asia-Pacific region (excluding Japan). More news on: G1 Therapeutics, Inc., Healthcare stocks news, Read more ...
- G1 to receive $6 million upfront payment, sales royalties and up to $40 million in future milestone payments - Genor to lead clinical development, regulatory submissions and commercialization of lerociclib in Asia-Pacific RESEARCH TRIANGLE PARK, N.C. and SHANGHAI, China, June 22, 20...
June holds plenty of catalysts for biotechnology stocks -- especially those specializing in cancer treatments. Investors with extra cash on the sidelines may be able to capture some exciting cancer stocks at attractive prices. These small-cap biotechnology stocks when held in the long term can...
G1 Therapeutics (NASDAQ: GTHX ) inks an agreement with Hercules Capital for up to $100M in debt financing in four tranches. More news on: G1 Therapeutics, Inc., Healthcare stocks news, Read more ...
RESEARCH TRIANGLE PARK, N.C., June 01, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that the company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC ) for up to $100 million. G1 p...
- Trilaciclib significantly reduced myelosuppression and need for related supportive care interventions for patients with small cell lung cancer (SCLC) receiving chemotherapy - New Drug Application (NDA) submission for trilaciclib in SCLC on track for completion in 2Q20 RESEARCH T...
News, Short Squeeze, Breakout and More Instantly...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib in Combination with a TROP2 Antibod...
RESEARCH TRIANGLE PARK, N.C. and BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, and Pepper Bio, the world’s first transomics drug discovery and development company, announced a global licensing agreement (excluding t...